Trial · NCT07888192
Dexametedomidine Ketamine Infusion Versus Dexametedomidine Propofol Infusion in Non-compliant Agitated Patients on Continuous Positive Airway Pressure (CPAP) Mask Ventilation in the Intensive Care Unit
NCT07888192, Not applicable, Not yet recruiting, Ain Shams University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dexametedomidine Ketamine Infusion Versus Dexametedomidine Propofol Infusion in Non-compliant Agitated Patients on Continuous Positive Airway Pressure (CPAP) Mask Ventilation in the Intensive Care Unit. Trials, record NCT07888192. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07888192
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Dexametedomidine Ketamine Infusion Versus Dexametedomidine Propofol Infusion in Non-compliant Agitated Patients on Continuous Positive Airway Pressure (CPAP) Mask Ventilation in the Intensive Care Unit
- NCT number
- NCT07888192
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Ain Shams University
- Conditions
- CPAP Ventilation, Sedation, Hemodynamics Instability
- Interventions
- Group DK will receive dexmedetomidine (0.2-1.4 μg/kg/hour) and ketamine (0.5 mg/kg/hr)., Group KP will receive dexmedetomidine (0.2-1.4 μg/kg/hour) and propofol (2-4 mg/kg/hr).(
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The effect of each type of sedation on the outcome of the CPAP as for more compliant patient and lesser side effects | 48 hours | The first primary efficacy end point will be the proportion of time in target sedation range (RASS score, 0 to -3) without use of rescue therapy of the total duration of study drug infusion. |
| Secondary | • Sedation level and efficacy | 48 hours | The level and adequacy of sedation will be assessed using the Richmond Agitation-Sedation Scale (RASS). RASS scores will be recorded at predefined assessment time points during the 48-hour study period. |
| Secondary | • Oxygen saturation | 48 hour | Peripheral oxygen saturation (SpO₂, %) will be recorded throughout the 48-hour assessment period. |
| Secondary | • Adverse effects of dexmedetomidine | 48 hour | * Bradycardia: heart rate \<60 beats/minute. * Hypotension: a reduction in systolic blood pressure or mean arterial pressure of \>20% from the patient's baseline value. * Increased urine output: urine output \>150 mL/hour. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07888192
GET https://conductscience.org/api/trials/v1/NCT07888192/registered